Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Gross Profit: 2019-2025

Historic Gross Profit for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to $7.9 million.

  • Nurix Therapeutics' Gross Profit fell 37.29% to $7.9 million in Q3 2025 from the same period last year, while for Aug 2025 it was $83.7 million, marking a year-over-year increase of 48.32%. This contributed to the annual value of $54.5 million for FY2024, which is 29.15% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Gross Profit of $7.9 million as of Q3 2025, which was down 82.08% from $44.1 million recorded in Q2 2025.
  • Nurix Therapeutics' 5-year Gross Profit high stood at $44.1 million for Q2 2025, and its period low was $5.0 million during Q1 2021.
  • In the last 3 years, Nurix Therapeutics' Gross Profit had a median value of $15.2 million in 2023 and averaged $18.4 million.
  • In the last 5 years, Nurix Therapeutics' Gross Profit plummeted by 60.58% in 2024 and then spiked by 264.34% in 2025.
  • Nurix Therapeutics' Gross Profit (Quarterly) stood at $7.4 million in 2021, then decreased by 8.29% to $6.8 million in 2022, then spiked by 123.49% to $15.2 million in 2023, then decreased by 12.37% to $13.3 million in 2024, then plummeted by 37.29% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $44.1 million for Q2 2025, and $18.5 million during Q1 2025.